Concepedia

Chandramani Singh

CS

27

Publications

1.9K

Citations

19

H-Index

2001

Active since

Affiliations

All India Institute of Medical Sciences(Current)

Bharat Biotech (India)

Nizam's Institute of Medical Sciences

Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences

ICMR-National Institute of Virology

Chandramani Singh is an author at All India Institute of Medical Sciences specializing in medicine, vaccine safety, and covid-19.

ORCID

Top concepts

Publications per year

2001–2023

27

Publications

27

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 433 citations · Full text

, , +6

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 360 citations · Full text

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · The Lancet · 2021 · 358 citations · Full text

, , +7

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · 2021 · 79 citations · Full text

, , +17

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)

Chandramani Singh, Savita Verma, Prabhakar Reddy et al. · npj Vaccines · 2023 · 74 citations · Full text

Rows per page

1–5 of 27